Cite
HARVARD Citation
Badar, T. et al. (2021). Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 127 (7), pp. 1039-1048. [Online].